abstract |
FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) Provided is a novel treatment method for cancer tumors to which endocrine therapy is applied, using pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Also, a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of a tumor to which endocrine therapy is applied, characterized in that it is used in combination with endocrine therapy, and related compounds, uses, methods, provide a combination. |